Belgium
· Delayed Price · Currency is EUR Hyloris Pharmaceuticals Company Description
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs.
The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation.
It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases.
In addition, the company offers other value-added products comprising Tranexamic Acid Oral Rinse for preventing and treating excessive bleeding in patients on blood thinners undergoing dental procedures; Alenura to treat pain associated with interstitial cystitis/bladder pain syndrome; Miconazole/Domiphen Bromide cream for recurrent vulvovaginal candidiasis; PTX-252 to treat acute myeloid leukemia; Atomoxetine oral Liquid for the treatment of attention deficit hyperactivity disorder; HY-083 to treat idiopathic rhinitis; HY-088 for hypophosphatemia; HY-090 to treat burning mouth syndrome; and HY-091 for vulvar lichen sclerosis.
The company was incorporated in 2012 and is headquartered in Liège, Belgium.
| Country | Belgium |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Stijn Van Rompay |
Contact Details
Address: Boulevard Patience et Beaujonc N°3/1 Liège, 4000 Belgium | |
| Phone | 32 4 346 02 07 |
| Website | hyloris.com |
Stock Details
| Ticker Symbol | HYL |
| Exchange | Euronext Brussels |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | BE0974363955 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stijn Van Rompay | Co-Founder, Chief Executive Officer and Director |
| Thomas Jacobsen | Co-Founder, Chief Business Development Officer and Executive Director |
| Jean-Luc Vandebroek | Chief Financial Officer |
| Dr. Dietmar Aichhorn Ph.D. | Chief Operating Officer |
| Sven Watthy | Investor Relations Manager and Communications manager |
| Koenraad Van Der Elst | Chief Legal Officer |